#1 Clinical Trials Search in Europe

Ipn01194

A new drug called IPN01194 is currently being studied in clinical trials for patients with advanced solid tumors. This article will provide an overview of the ongoing research, including the drug’s potential benefits, how it’s being tested, and what patients can expect if they participate in the trial.

Table of Contents

What is IPN01194?

IPN01194 is a new drug currently being studied for its potential to treat various types of advanced solid tumors[1]. It is classified as an ERK1/2 inhibitor, which means it targets specific proteins involved in cancer growth[1]. This medication is still in the early stages of research, specifically in what’s called a “first-in-human” study, where it’s being tested in people for the first time[1].

What conditions does IPN01194 target?

IPN01194 is being investigated for its potential to treat several types of advanced solid tumors. These include:

  • Melanoma: A type of skin cancer[1]
  • Head and Neck Squamous Cell Carcinoma: Cancer that begins in the squamous cells that line the moist surfaces inside the head and neck[1]
  • Pancreatic Ductal Adenocarcinoma: The most common type of pancreatic cancer[1]
  • Colorectal Cancer: Cancer that starts in the colon or rectum[1]

The term “advanced solid tumors” refers to cancers that have spread from where they started to nearby tissues or other parts of the body[1].

How does IPN01194 work?

IPN01194 is an ERK1/2 inhibitor[1]. ERK1 and ERK2 are proteins that play a crucial role in cell growth and division. In many types of cancer, these proteins become overactive, leading to uncontrolled cell growth. By inhibiting ERK1/2, IPN01194 aims to slow down or stop the growth of cancer cells.

The Clinical Trial: What You Need to Know

The ongoing study of IPN01194 is a Phase I/IIa clinical trial[1]. This type of study is designed to:

  1. Phase I: Determine the safe dose range and assess how the body processes the drug[1]. This phase will test different dose levels to find the right balance between effectiveness and safety.
  2. Phase IIa: Further evaluate the safety and start to assess the effectiveness of the drug in treating specific types of tumors[1].

The study is divided into three periods:

  1. Screening period: Up to 28 days to assess if a person is eligible to participate in the study[1].
  2. Treatment period: At least 28 days of treatment with regular check-ups[1].
  3. Follow-up period: For Phase IIa participants, this involves phone contact every 3 months until the end of the study or the participant’s death[1].

How is IPN01194 administered?

IPN01194 is taken orally (by mouth) in cycles of 28 days[1]. The exact dose will depend on the findings of the Phase I study. Participants will continue to receive the drug until:

  • The side effects become too severe
  • The cancer progresses
  • The participant requests to stop
  • The doctor decides to stop the treatment[1]

Safety and Effectiveness

The primary goals of this study are to assess the safety and effectiveness of IPN01194. Researchers will be looking at several factors, including:

  • The percentage of participants who experience dose-limiting toxicities (side effects that are severe enough to prevent increasing the dose)[1]
  • The types and frequency of side effects[1]
  • How many participants need to interrupt or stop treatment due to side effects[1]
  • The objective response rate (ORR), which measures how many patients’ tumors shrink or disappear with treatment[1]

Potential Benefits of IPN01194

While it’s too early to know for certain, researchers hope that IPN01194 will show benefits such as:

  • Tumor shrinkage or disappearance (measured by the objective response rate)[1]
  • Longer time before the cancer progresses (progression-free survival)[1]
  • Better control of the disease (disease control rate)[1]

Possible Side Effects

As with any new drug, the full range of side effects is not yet known. The study will carefully monitor for any adverse events, which are any undesirable medical occurrences during the trial[1]. Some specific things they’ll be watching for include:

  • Changes in heart rhythm (measured by QT interval on an ECG)[1]
  • Any side effects that might require changing the dose or stopping treatment[1]

Future Prospects

If IPN01194 shows promising results in this early-stage trial, it may proceed to larger studies involving more patients. The ultimate goal would be to develop a new treatment option for patients with advanced solid tumors, particularly those that have not responded well to existing treatments.

Aspect Details
Drug Name IPN01194
Drug Type ERK1/2 inhibitor
Administration Oral (by mouth)
Target Conditions Advanced solid tumors, including melanoma, head and neck squamous cell carcinoma, pancreatic ductal adenocarcinoma, and colorectal cancer
Trial Phases Phase I (dose escalation) and Phase IIa (cohort expansion)
Treatment Duration Minimum 28 days, with potential for longer treatment
Primary Outcomes Safety, tolerability, and objective response rate
Secondary Outcomes Pharmacokinetics, pharmacodynamics, duration of response, progression-free survival, and disease control rate

FAQ

  • What is IPN01194? IPN01194 is a new drug being tested for treating advanced solid tumors. It's an ERK1/2 inhibitor, which means it targets specific proteins involved in cancer growth.
  • What types of cancer is IPN01194 being tested for? The trial is focusing on advanced solid tumors, including melanoma, head and neck squamous cell carcinoma, pancreatic ductal adenocarcinoma, and colorectal cancer.
  • How is the drug administered? IPN01194 is taken orally (by mouth) in cycles of 28 days.
  • What are the phases of the clinical trial? The trial has two main parts: Phase I, which focuses on finding the right dose, and Phase IIa, which tests the drug's effectiveness in specific tumor types.
  • How long does the trial last? The treatment period lasts at least 28 days, with follow-up visits. Some participants may continue treatment for longer if they're benefiting from the drug.

Ongoing Clinical Trials on Ipn01194

  • Study of IPN01194 for Adults with Advanced Solid Tumors, Including Melanoma, Head and Neck Cancer, Pancreatic Cancer, and Colorectal Cancer

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    France Spain

Glossary

  • Advanced solid tumors: Cancers that occur in organs or tissues and have spread from their original site to nearby tissues or other parts of the body.
  • ERK1/2 inhibitor: A type of drug that blocks specific proteins (ERK1 and ERK2) involved in cancer cell growth and survival.
  • Dose escalation: A process in clinical trials where the amount of drug given is gradually increased to find the safest and most effective dose.
  • Pharmacokinetics: The study of how a drug moves through the body, including how it's absorbed, distributed, metabolized, and eliminated.
  • Pharmacodynamics: The study of how a drug affects the body, including its mechanism of action and therapeutic effects.
  • Dose limiting toxicity (DLT): Side effects that are severe enough to prevent increasing the dose of a drug in a clinical trial.
  • Objective response rate (ORR): The percentage of patients whose cancer shrinks or disappears after treatment.
  • RECIST: Response Evaluation Criteria in Solid Tumors, a standard way to measure how well a cancer treatment is working.
  • Progression-free survival (PFS): The length of time during and after treatment that a patient lives without their cancer getting worse.
  • Disease control rate (DCR): The percentage of patients whose cancer shrinks, disappears, or remains stable after treatment.

References

  1. https://clinicaltrials.gov/study/NCT06305247